Jafar Amani

20PUBLICATIONS
48CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Molecular targetsInnate immunityMedical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Nov 29, 2025
Chitosan nanoparticles loaded with ribavirin, carboplatin, and thyme oil downregulate SNQ2, ERG11, CDR1, and MDR1 in Candida strains.

Shima Aghaei, Mohammad Hossein Yadegari, Masoumeh Rajabibazl

|Jul 28, 2025
Evaluation of Antimicrobial Activity of Novel Chimeric M-PEX12 Peptide Against Acinetobacter baumannii.

Yasin Rakhshani, Hamideh Mahmoodzadeh Hosseini, Seyed Ali Mirhosseini

|Jul 28, 2025
Design and Characterization of Ricin Based Immunotoxins Against EPHA2 Receptor for Breast Cancer Therapy: An In-Silico Study.

Atefeh Faraz, Jafar Amani, Sedigheh Arbabian

|Dec 28, 2024
Design and Cytotoxicity Evaluation of a Cancer-targeting Immunotoxin Based on a Camelid Nanobody-PE Fusion Protein.

Mona Khoshbakht, Mohammad Mahdi Forghanifard, Hossein Aghamollaei

|Oct 13, 2024
In silico and in vitro evaluation of a PE38 and Nb-based recombinant immunotoxin targeting the GRP78 receptor in cancer cells.

Mona Khoshbakht, Mohammad Mahdi Forghanifard, Hossein Aghamollaei

|Sep 07, 2024
Comments on "Comparative Immunogenicity and Neutralization Potency of Four Approved COVID-19 Vaccines in BALB/c Mice".

Ali Saffaei, Jafar Amani, Jafar Salimian

Pageof 4